

IF NO REIMBURSEMENT

Special Solidarity Fund





BELGIUM

Recent and planned developments in pharmaceutical policies 2019 Special topic: Patient-based reimbursement decisions

CHANGES IN PRICING CHANGES IN REIMBURSEMENT 01.2019: Tarification in hospitals 01.2019: Reform economic margin at 85% of the reimbursed price pharmacist (outpatient) **04.2019**: virtual margin of 10 % in 04.2019: volume cliff cheap(est) Q3/4.2019: review diabetes, **04.2019**: ceiling prices in hospitals haemophilia, anti-HIV, renal cancer immunoglobulins **OTHER CHANGES** Mandatory use of Authenic Introduction of 'cheap Mandatory e-prescription for prescription' + 'cheapest Source of Medicines medicines for ambulatory delivery' in hospitals patients **SPECIAL TOPIC: Patient-based reimbursement decisions** REIMBURSEMENT PRINCIPLE reimbursement of medicines versus reimbursements of acts/diagnostic tests → what is the goal of health care systems? → Challenge: The primary goal of health care policy = 2 different technologies/processes/expertise to maximize the health of the **EFFICIENCY** population within the limits of the 2 different commissions/timelines/budgets/... (TMC vs. CRM) available resources, and quick technological & scientific evolution within an ethical framework built on EQUITY equity and solidarity principles. health care reimbursement procedures should allow for treatment and test REIMBURSEMENT FUNDING From July 2019: medicine simultaneously reimbursed MEA: Pay 4 Performance / Cure / Result with predictive test + follow-up by register College of Medical Doctors for Orphan Drugs (CMDOD)